Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent workshop at Pembroke College, Oxford, provided a showcase for research within the Arthritis Therapy Acceleration Programme (A-TAP) aimed at speeding up the delivery of new drugs for immune-mediated inflammatory disease (IMIDs).

A-TAP logo

The workshop was organised by the Kennedy Institute’s Director of Clinical Research and A-TAP lead, Prof Chris Buckley, to raise awareness of A-TAP and the funding opportunities it provides to support experimental medicine studies.

In opening remarks, Chris highlighted the importance of experimental medicine to overcome barriers in drug discovery. He explains, “Developments in our understanding of the genetic and cellular basis of disease have revealed that diseases traditionally classified as anatomically distinct share much more in common that previously recognized. Coupled with advances in biologic and cellular therapy and innovations in clinical trial design, it is now possible to run trials that have pathology-based outcome measures with one drug being studies across a ‘basket’ of different IMIDs”.

A-TAP was launched by the Universities of Oxford and Birmingham in 2017 to apply this new approach to trial design for development of novel treatments based on the underlying causes of inflammatory disease. The programme is supported by a £7M award from the Kennedy Trust for Rheumatology Research.

One way in which A-TAP facilitates clinical studies is to improve access to patients and diseased tissue samples. During the workshop, Dr Andrew Filer, an A-TAP investigator at the University of Birmingham, described his work on the Birmingham Early Arthritis Cohort (BEACON) to biopsy joint tissues when patients first show signs of inflammation in their joints. This approach is enabling research across the A-TAP network into early predictors and drivers of arthritis.

Robust and accurate tools to measure biological markers in tissues are also crucial to understand disease processes and how they are affected by drugs. Led by Dr Clare Verrill, University of Oxford, workshop participants also learned about the application of artificial intelligence approaches to measure pathology based markers across tissue samples from different types of inflammatory disease.

The workshop also gave a flavour of two new clinical studies enabled by A-TAP. These are exploring the effect of anti TNF therapy on tissue based markers in Rheumatoid Arthritis and Inflammatory bowel disease as well as the effect of three different biological therapies on cell populations in patients with ankylosing spondylitis

For more information about A-TAP and funding opportunities for Oxford and Birmingham based projects in the area of inflammatory arthritis, please contact A-TAP Operations Manager, Dr Claire Potter.

 

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.